No takes yet. Share an insight, caveat, or question.
Cohort study shows adjuvant imatinib delays recurrence and improves survival in high-risk GISTs with KIT exon 9 mutations, suggesting treatment benefits.
Napolitano et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: